POST-TEST

New Biological Insights and Recent Therapeutic Advances in the Management of Acute and Chronic Leukemias and Myelodysplastic Syndromes

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING. 1. Which of the following is an adverse 5. For patients with previously treated event associated with idelalisib acute lymphoblastic leukemia (ALL) and treatment in patients with chronic remaining minimal residual disease, the lymphocytic leukemia (CLL)? bispecific T-cell engaging monoclonal a. Transaminitis antibody ______resulted in b. Pneumonitis high complete response rates in the bone marrow. c. Colitis a. Obinutuzumab d. Both a and b b. Blinatumomab e. All of the above c. Ofatumumab 2. The improvement in progression-free survival when sorafenib was added to 6. Intensive treatment regimens developed standard induction therapy for patients for pediatric patients with ALL have also aged 60 years or younger with newly been shown to be efficacious in older diagnosed acute myeloid leukemia (AML) adolescents and young adults with this was restricted to patients with FLT3-ITD disease. mutation-positive disease. a. True a. True b. False b. False 7. ______is an adverse event 3. For elderly patients with AML who associated with the protein synthesis were not eligible for chemotherapy, inhibitor omacetaxine mepesuccinate the addition of the polo-like kinase in the management of chronic myeloid inhibitor volasertib to low-dose leukemia. cytarabine improved efficacy in terms of a. Gastrointestinal toxicity ______. b. Cytopenia a. Response rate c. Both a and b b. Median event-free survival d. None of the above c. Median overall survival d. Both b and c 8. The achievement of partial responses with lymphocytosis in patients with CLL e. All of the above may be observed as part of the clinical pattern of response associated with 4. Lenalidomide therapy did not result in ______treatment. improved rates of transfusion indepen- dence when compared to placebo for a. Single-agent idelalisib patients with lower-risk myelodysplastic b. Single-agent ibrutinib syndromes lacking the deletion 5q c. Both a and b karyotypic abnormality and unresponsive or refractory to erythropoiesis stimu- lating agents. a. True b. False